{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009299","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.059502+00:00","generated_at":"2026-05-15T09:21:13.451903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Talphera reports Q4 net loss $3.8M; NEPHRO CRRT study 50% enrolled, all 12 sites active","bullets":["Cash and investments $20.4M at Dec 31, 2025; net loss $3.8M ($0.06 per share) vs $1.9M ($0.07) in Q4 2024.","NEPHRO CRRT registrational study reached 35 of 70 patients (50% enrollment); all 12 sites now enrolling.","Closed $4.1M tranche of private placement upon achieving 35-patient milestone; total financing proceeds $1.6M in October 2025.","Combined R&D and SG&A expenses $3.5M in Q4 2025 vs $3.0M in Q4 2024; increase driven by Niyad development costs.","2026 cash operating expense guidance $17M-$18M, up from ~$13M in 2025, including finalizing CRRT trial and CMC/validation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009299","json":"https://secwatch.observer/filing/0001437749-26-009299.json","markdown":"https://secwatch.observer/filing/0001437749-26-009299.md","text":"https://secwatch.observer/filing/0001437749-26-009299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926009299/0001437749-26-009299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774926009299/acrx20260321_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:21:13.451903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}